Cleo Diagnostics

Cleo Diagnostics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Cleo Diagnostics (COV.AX) as of Nov 3, 2026 is 72.82 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 54.09 % — a change of 34.64% (higher).

FCF Conversion

72.82 %

YoY

34.64%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Cleo Diagnostics is 2025 72.82 % . FCF Conversion Rate (FCF/EBITDA) of Cleo Diagnostics was 2024 54.09 % . It decreases by 34.64% higher compared to the previous year.

The Cleo Diagnostics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2022
455.27 AUD
Jan 1, 2023
59.25 AUD
Jan 1, 2024
54.09 AUD
Jan 1, 2025
72.82 AUD
The Cleo Diagnostics FCF Conversion history
YEARFCF ConversionYoY
72.82 %+34.64%
54.09 %-8.71%
59.25 %-86.99%
455.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cleo Diagnostics Stock analysis

What does Cleo Diagnostics do? Cleo Diagnostics Ltd develops non-invasive blood-based IVD tests for ovarian cancer detection. The company's three-phased strategy includes the Triage Test for pre-surgical assessment of ovarian masses, the Recurrence Test for post-surgical monitoring of cancer recurrence, and the Screening Test for early detection in asymptomatic women. The CLEO Test Kit detects the protein biomarker CXCL10 in blood samples. These products target healthcare providers, oncologists, and diagnostic laboratories seeking advanced tools for ovarian cancer management. The company generates revenue through the sale of these diagnostic tests and kits to medical institutions and laboratories in Australia and potentially international markets. The Triage Test helps determine malignancy before oncologist referral, the Recurrence Test identifies cancer recurrence after surgery and chemotherapy, and the Screening Test enables early detection in symptom-free women. Cleo Diagnostics Ltd focuses on delivering these specialized tests to address unmet needs in ovarian cancer diagnostics. Revenue streams are derived from the commercialization of these three test phases and the CLEO Test Kit, targeting medical professionals and healthcare facilities requiring accurate and non-invasive diagnostic solutions. Cleo Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cleo Diagnostics stock

FCF Conversion Rate (FCF/EBITDA) of Cleo Diagnostics is 72.82 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Cleo Diagnostics changed from 54.09 % to 72.82 %, representing a 34.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Cleo Diagnostics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Cleo Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Cleo Diagnostics

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Cleo Diagnostics